Skip to content

Study · Randomized controlled trial · n = 146 · 2011

2 results

Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial.

Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC

Fertility and sterility16 Jul 2010Cited by 37 (Europe PMC)

PMID20637457 (opens in a new tab)DOI10.1016/j.fertnstert.2010.05.052 (opens in a new tab)PepBankPUB-20637457
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF patients, flexible cetrorelix administration did not significantly change LH-rise incidence compared with fixed administration.

    In plain wordsIn IVF patients, flexible cetrorelix administration did not significantly change LH-rise incidence compared with fixed administration.

    Peptide
    Cetrorelix
    Outcome
    No significant changeIncidence of LH rise
    Study

    n = 146

    Comparator
    Fixed day-6 cetrorelix protocol
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    LH rise incidence
    11%
    Flexible
    LH rise incidence
    15.1%
    Fixed
    Incidence difference
    −4.1%
    Flexible versus fixed
    95% confidence interval
    −15.4 to 7.1%
    Incidence difference

    Source sentences

    Summary
    No statistically significant difference was observed between the flexible and fixed groups regarding the incidence of LH rise, which was lower in the flexible group (11.0% vs. 15.1%, difference -4.1%, 95% confidence interval -15.4% to +7.1%).
    4 context sentences
    Summary · context
    Randomized controlled trial.
    Summary · context
    Patients undergoing in vitro fertilization (n = 146).
    Summary · context
    GnRH antagonist cetrorelix (0.25 mg/d) was started either on day 6 of stimulation (fixed group) or when LH was >10 IU/L, and/or a follicle with mean diameter >12 mm was present,
    Summary · context
    Incidence of LH rise.
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF patients, no LH surges were observed with either flexible or fixed cetrorelix administration.

    In plain wordsIn IVF patients, no LH surges occurred with either flexible or fixed cetrorelix administration.

    Peptide
    Cetrorelix
    Outcome
    Not applicableLH surges
    Study

    n = 146

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    No LH surges were observed in any of the patients studied.
    3 context sentences
    Summary · context
    Randomized controlled trial.
    Summary · context
    Patients undergoing in vitro fertilization (n = 146).
    Summary · context
    GnRH antagonist cetrorelix (0.25 mg/d) was started either on day 6 of stimulation (fixed group) or when LH was >10 IU/L, and/or a follicle with mean diameter >12 mm was present,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01005784

Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation

Aristotle University Of Thessalonikin = 146Jun 2005 to Mar 2008

Subfertility

Trial pageClinicalTrials.govUpdated 2 Nov 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.